New business models for pharmaceutical research and development as a global public good considerations for the WHO European Region

Public concern has been increasing about the high prices of novel medicines, limits on availability and access, and the strain on health-care budgets across all countries. Addressing these challenges requires scrutinizing the underlying system of research and development (R&D) that produces thes...

Full description

Bibliographic Details
Main Authors: Moon, Suerie, Vieira, Marcela (Author), Alonso Ruiz, Adrián (Author), Navarro, Danielle (Author)
Corporate Authors: Oslo Medicines Initiative, World Health Organization Regional Office for Europe
Format: eBook
Language:English
Published: Copenhagen, Denmark World Health Organization 2022, [2022]
Series:Oslo medicines initiative technical report
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02424nam a2200301 u 4500
001 EB002153142
003 EBX01000000000000001291268
005 00000000000000.0
007 tu|||||||||||||||||||||
008 230403 r ||| eng
020 |a 9789289058124 
100 1 |a Moon, Suerie 
245 0 0 |a New business models for pharmaceutical research and development as a global public good  |h Elektronische Ressource  |b considerations for the WHO European Region  |c Suerie Moon, Marcela Vieira, Adrián Alonso Ruiz, Danielle Navarro 
260 |a Copenhagen, Denmark  |b World Health Organization  |c 2022, [2022] 
300 |a 1 PDF file (x, 63 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
700 1 |a Vieira, Marcela  |e [author] 
700 1 |a Alonso Ruiz, Adrián  |e [author] 
700 1 |a Navarro, Danielle  |e [author] 
710 2 |a Oslo Medicines Initiative 
710 2 |a World Health Organization  |b Regional Office for Europe 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Oslo medicines initiative technical report 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK587828  |3 Volltext 
082 0 |a 610 
082 0 |a 330 
520 |a Public concern has been increasing about the high prices of novel medicines, limits on availability and access, and the strain on health-care budgets across all countries. Addressing these challenges requires scrutinizing the underlying system of research and development (R&D) that produces these outcomes. Increasing policy attention has turned towards how to make the outputs of the innovation process accessible to all, and what changes to the current innovation model are needed. This report analyses the implications and challenges of transforming medicines - which have to date largely been treated as national private goods - into "global public goods" (GPGs). It describes the current model for pharmaceutical R&D and assesses how well it performs in producing GPGs along three dimensions: generation of pharmaceutical knowledge, its global availability and its global affordability. It then investigates alternative business models, including those implemented for COVID-19, and analyses how well they may be able to produce GPGs, concluding with proposals for consideration by public and private actors in the WHO European Region that could reorient the R&D system towards delivering GPGs